US OptionsDetailed Quotes
BMEA250117C17500
- 0.20
- 0.000.00%
15min DelayClose Dec 24 13:00 ET
0.00High0.00Low
0.20Open0.20Pre Close0 Volume1.02K Open Interest17.50Strike Price0.00Turnover381.27%IV341.40%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type0.1458Delta0.0595Gamma20.05Leverage Ratio-0.0189Theta0.0002Rho2.92Eff Leverage0.0023Vega
Biomea Fusion Stock Discussion
Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient population
Icovamenib was well-tolerated, with no adverse-event related discontinuations, no hypoglycemic events and no serious adverse events
Yet all the analysts are giving target price from a low 11$ to a 50/60 and above.
What's your take?
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
$KULR Technology (KULR.US)$ PR 12/17: Signs Service Agreement to Launch KULR ONE Space Battery. COH $13.4M good for 9 months✅
$Wearable Devices (WLDS.US)$ PR 12/17:...
Biomea Fusion Inc - Icovamenib Meets Primary Endpoint With Significant Reduction in Hba1C
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
Tuesday, 17th December at 8:10 am
• Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient population
• Best response achieved in target, beta-cell deficient patients on one or more antidiabetic agents at baseline, showing a placeb...
No comment yet